Creandum invests in Atlas Bio
Funding Provisional 90% confidence first seen
Swiss biotech Atlas Bio announced that it raised $12.5M, including a $10M Seed round led by Creandum, alongside a previously unannounced pre-Seed led by First Momentum Ventures and LEA Partners. The funding supports Atlas Bio’s foundational AI model for in silico clinical trials, aiming to de-risk drug development and reduce reliance on animal testing by simulating efficacy and safety before Phase II. The report notes Creandum partner Katharina Wilhelm will join Atlas Bio’s board, and the round is positioned to speed up timelines and lower costs for clinical development.
The deal
Atlas Bio $12.5 million Other · announced 27 Oct 2026
Investors Creandum First Momentum Ventures LEA Partners
Deal terms as reported in the coverage below.
Decision brief
- What changed
- Swiss biotech Atlas Bio emerged from stealth and disclosed $12.5 million in total funding, including a $10 million Seed round led by Creandum plus a previously unannounced pre-Seed led by First Momentum Ventures and LEA Partners. The company said it is using the capital to build a foundational AI model for in silico clinical trials based on roughly 2 million RNA readouts from human tissue.
- Why it matters
- For healthcare, biotech, and pharma decision-makers, this is a financing signal behind an AI approach aimed at cutting clinical development cost and time by simulating efficacy and safety before Phase II. If Atlas Bio’s approach proves technically and regulatorily credible, it could affect how partners evaluate preclinical evidence, vendor relationships, and the economics of trial design; however, the coverage supports the company’s intent and funding, not validated outcomes.
- Evidence
- The event is supported by one Tech.eu report stating Atlas Bio raised $12.5 million, that Creandum led the $10 million Seed round, and that the company’s model is trained on about 2 million RNA readouts from human tissue to enable 12-week virtual simulations. Because the coverage comes from a single outlet and largely relays company-announced details, independent corroboration in the provided material is limited.
- What remains uncertain
- The coverage does not verify model performance, regulatory acceptance, customer adoption, or whether virtual simulations can reliably reduce Phase II risk in practice. It also leaves open key assumptions about data quality, generalizability across indications, and how quickly pharma partners would integrate such tools into development workflows.
- Monitor next
- Watch for disclosed pharma partnerships, peer-reviewed validation, or regulator-facing evidence that Atlas Bio’s simulations can inform trial decisions beyond internal R&D claims.
Analytical support, not advice — assumptions and open questions stated above.